Small interfering RNA (siRNA) Therapeutics- Competitive Landscape, Technology and Pipeline Insights, 2015

Date: 2015-11
Pages:318
Price:

“The Report, “Small interfering RNA (siRNA) Therapeutics- Competitive Landscape, Technology and Pipeline Insights, 2015” depicts the current pipeline scenario of siRNA therapies under development. Many targets which were difficult to reach by traditional small-molecule and protein have been identified by therapeutics based on RNA interference (RNAi). RNA interference (RNAi), a process in recovery Phase, is still keeping the expectations of the many mid Pharma companies at a higher end with blockbuster deals and adequate delivery technologies.

This report analysis the current frontrunners in siRNA therapies with leading technologies and major acquisitions and deals seen in past 3 years. Report highlights the 16 different types of technologies that have been used lately to enhance the siRNA development in different stages of development.

There are 13+ active companies dealing with 70+ siRNA therapies. Mostly siRNA is being studied for oncology area with 24 siRNA therapies under development by major pharma companies followed by 11 therapies for infectious diseases and 8 siRNA therapies in Ophthalmology. Currently 28 siRNA are in clinical stage of development with many mid-stage products.

Contact With Us
Join templatemonster at google+
Customized Research
Request Sample